Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists · 2009
Association between antipsychotic combination therapy and treatment adherence among individuals with bipolar disorder.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gianfrancesco Frank D, Sajatovic Martha, Tafesse Eskinder, Wang Ruey-Hua
Аннотация
BACKGROUND: This study investigated the effect on antipsychotic treatment adherence of combining quetiapine or risperidone with lithium, anticonvulsants, and/or antidepressants among bipolar individuals with predominantly manic/mixed or depressive symptoms.
METHODS: Treatment episodes with quetiapine or risperidone were identified from individuals with medical claims for bipolar/manic disorder. Multiple regression analysis was used to evaluate the impact of antipsychotic combinations on treatment adherence, as measured by intensity (medication possession ratio [MPR]) and treatment duration.
RESULTS: Among mixed/manic individuals, combination therapies were associated with lower antipsychotic MPRs than monotherapy (P< .05), with MPR decreasing with number of medications. Quetiapine showed a similar pattern among depressed individuals, whereas risperidone showed a weaker association. For both subgroups, antipsychotic combinations with anticonvulsants were associated with lower MPRs than combinations with lithium. For manic/mixed individuals, combining quetiapine with an anticonvulsant and lithium was associated with shorter treatment durations than quetiapine alone (P <or= .05). For manic/mixed individuals receiving risperidone, treatment duration was not affected by type of combination therapy. Among depressed subgroups, treatment duration was unrelated to combination therapy.
CONCLUSIONS: Adherence to quetiapine and risperidone may be affected by whether they are prescribed alone or as combination therapy, the combination strategy, and the predominant symptomatology of the individual.
METHODS: Treatment episodes with quetiapine or risperidone were identified from individuals with medical claims for bipolar/manic disorder. Multiple regression analysis was used to evaluate the impact of antipsychotic combinations on treatment adherence, as measured by intensity (medication possession ratio [MPR]) and treatment duration.
RESULTS: Among mixed/manic individuals, combination therapies were associated with lower antipsychotic MPRs than monotherapy (P< .05), with MPR decreasing with number of medications. Quetiapine showed a similar pattern among depressed individuals, whereas risperidone showed a weaker association. For both subgroups, antipsychotic combinations with anticonvulsants were associated with lower MPRs than combinations with lithium. For manic/mixed individuals, combining quetiapine with an anticonvulsant and lithium was associated with shorter treatment durations than quetiapine alone (P <or= .05). For manic/mixed individuals receiving risperidone, treatment duration was not affected by type of combination therapy. Among depressed subgroups, treatment duration was unrelated to combination therapy.
CONCLUSIONS: Adherence to quetiapine and risperidone may be affected by whether they are prescribed alone or as combination therapy, the combination strategy, and the predominant symptomatology of the individual.